|Bid||335.00 x 255900|
|Ask||337.30 x 42900|
|Day's Range||327.10 - 345.10|
|52 Week Range||2.87 - 345.10|
|PE Ratio (TTM)||-1,125.58|
|Earnings Date||Aug 16, 2017 - Aug 23, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
TEL AVIV, Israel, May 25, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...